RAD51C and cancer: This is the largest family-based study to date to estimate age-specific relative and absolute TOC and BC risks for RAD51C and RAD51D pathogenic variant carriers, confirming that RAD51C and RAD51D pathogenic variants are associated with TOC and BC risks, which vary by cancer-family history.